INTRAVITREAL FARICIMAB AS AN ADJUVANT IN THE MANAGEMENT OF TUBERCULAR UVEITIS.

Q3 Medicine Retinal Cases and Brief Reports Pub Date : 2025-03-01 DOI:10.1097/ICB.0000000000001542

Yasmine Alcibahy, Karina Julian, Maria Fernanda Bonilla, Ali Mohamed, Sarah Amrani, Aniruddha Agarwal

{"title":"INTRAVITREAL FARICIMAB AS AN ADJUVANT IN THE MANAGEMENT OF TUBERCULAR UVEITIS.","authors":"Yasmine Alcibahy, Karina Julian, Maria Fernanda Bonilla, Ali Mohamed, Sarah Amrani, Aniruddha Agarwal","doi":"10.1097/ICB.0000000000001542","DOIUrl":null,"url":null,"abstract":"Purpose: The objective of this study was to report the use of intravitreal faricimab used as an adjunct in the management of intraocular tuberculosis in a patient with occlusive retinal vasculitis and choroiditis.Methods: This is a case report.Results: A 27-year-old Asian man presented with bilateral choroiditis and occlusive retinal vasculitis complicated by retinal neovascularization and vitreous hemorrhage in one eye. The patient had a positive tuberculin skin test, indeterminate interferon-gamma release assay, and Ghon focus on chest radiography. With a diagnosis of intraocular tuberculosis, the patient was treated with antitubercular therapy. Owing to the significant vitreous hemorrhage, he underwent pars plana vitrectomy in one eye. The patient received bilateral faricimab. Within a week of the injection, he had a near-complete resolution of the extensive choroidal and retinal vascular inflammation.Conclusion: Intravitreal faricimab, given its angiopoietin-2 inhibition and antivascular endothelial growth factor action, maybe a helpful adjunct in intraocular tuberculosis. Whether angiopoietin-2 inhibition provides any additional benefit needs further evaluation in extensive studies.","PeriodicalId":53580,"journal":{"name":"Retinal Cases and Brief Reports","volume":" ","pages":"177-181"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retinal Cases and Brief Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ICB.0000000000001542","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The objective of this study was to report the use of intravitreal faricimab used as an adjunct in the management of intraocular tuberculosis in a patient with occlusive retinal vasculitis and choroiditis.

Methods: This is a case report.

Results: A 27-year-old Asian man presented with bilateral choroiditis and occlusive retinal vasculitis complicated by retinal neovascularization and vitreous hemorrhage in one eye. The patient had a positive tuberculin skin test, indeterminate interferon-gamma release assay, and Ghon focus on chest radiography. With a diagnosis of intraocular tuberculosis, the patient was treated with antitubercular therapy. Owing to the significant vitreous hemorrhage, he underwent pars plana vitrectomy in one eye. The patient received bilateral faricimab. Within a week of the injection, he had a near-complete resolution of the extensive choroidal and retinal vascular inflammation.

Conclusion: Intravitreal faricimab, given its angiopoietin-2 inhibition and antivascular endothelial growth factor action, maybe a helpful adjunct in intraocular tuberculosis. Whether angiopoietin-2 inhibition provides any additional benefit needs further evaluation in extensive studies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

将玻璃体内法尼单抗作为治疗结核性葡萄膜炎的辅助药物。

目的：报告一名患有闭塞性视网膜血管炎（ORV）和脉络膜炎的患者使用玻璃体内法尼单抗作为眼内结核（IOTB）的辅助治疗方法：病例报告：一名 27 岁的亚洲男性患者出现双侧脉络膜炎和闭塞性视网膜血管炎，其中一只眼睛并发视网膜新生血管和玻璃体出血。患者的结核菌素皮肤试验呈阳性，干扰素-γ释放测定结果不确定，胸片上有 Ghon 病灶。确诊为 IOTB 后，患者接受了抗结核治疗。由于玻璃体出血严重，他接受了单眼玻璃体旁切除术。患者接受了双侧法尼单抗注射。注射后一周内，广泛的脉络膜和视网膜血管炎症几乎完全消退：结论：鉴于法尼单抗具有血管生成素 2（ang2）抑制和抗血管内皮生长因子的作用，它可能是 IOTB 的一种有效辅助药物。至于血管生成素 2 抑制是否会带来额外的益处，还需要在广泛的研究中进一步评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊